Ranbaxy again finds itself involved with the US legal system and is accused of “…conspiring to manipulate the FDA and block competition in the generic drug business”. This was reportedly accomplished by a practice of filing “false or incomplete paperwork” to gain the 180-exclusivity as the generic company first to file. According to Law360, Michigan retailer Meijer brought the putative class action suit in Massachusetts federal court and Bloomberg provides details on May 14, 2015. According to the complaint, “Ranbaxy’s actions broke US antitrust law and amounted to a racketeering scheme that blocked competitors from getting generic medicines to market faster”. In the consent decree agreement from January 2012 and the legal fines paid in May 2013, Ranbaxy became the early poster child for data integrity issues aided by an internal whistleblower. The timeline of actions taken against Ranbaxy has its own page on the FDA website with links to the warning letters, import alerts, consent decree agreement and other enforcement actions. Sun Pharmaceuticals is now involved because they recently completed the purchase of Ranbaxy.